These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38662853)

  • 1. Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis.
    Zheng B; Wang M; McKenna K; Shapiro L; Silver R; Csuka ME; van den Hoogen F; Robinson D; Pauling JD; Hummers L; Krieg T; Del Galdo F; Spiera R; Jones N; Khalidi N; Vacca A; de Vries-Bouwstra JK; Gordon J; Baron M;
    Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1806-1812. PubMed ID: 38662853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.
    Zheng B; Wang M; Stevens W; Proudman S; Nikpour M; Baron M; ;
    Semin Arthritis Rheum; 2022 Apr; 53():151973. PubMed ID: 35149318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS).
    Zheng B; Hudson M; Wang M; Baron M;
    Arthritis Res Ther; 2020 Jun; 22(1):132. PubMed ID: 32503616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
    Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE
    Arthritis Care Res (Hoboken); 2016 Feb; 68(2):167-78. PubMed ID: 26806474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
    Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE
    Arthritis Rheumatol; 2016 Feb; 68(2):299-311. PubMed ID: 26808827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.
    Khanna D; Huang S; Lin CJF; Spino C
    Ann Rheum Dis; 2021 May; 80(5):641-650. PubMed ID: 33257497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design.
    Domsic RT; Gao S; Laffoon M; Wisniewski S; Zhang Y; Steen V; Lafyatis R; Medsger TA
    Rheumatology (Oxford); 2021 Oct; 60(10):4662-4670. PubMed ID: 33506859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do We Have Good Activity Indices in Systemic Sclerosis?
    Groseanu L; Petrescu S; Balanescu A; Bojinca V; Opris-Belinski D; Berghea F; Mazilu D; Saulescu I; Borangiu A; Daia-Iliescu S; Constantinescu C; Cobilinschi C; Abobului M; Negru MM; Ionescu R
    Curr Rheumatol Rev; 2022; 18(1):39-47. PubMed ID: 34517805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).
    Khanna D; Distler O; Avouac J; Behrens F; Clements PJ; Denton C; Foeldvari I; Giannini E; Huscher D; Kowal-Bielecka O; Lovell D; Matucci-Cerinic M; Mayes M; Merkel PA; Nash P; Opitz CF; Pittrow D; Rubin L; Seibold JR; Steen V; Strand CV; Tugwell PS; Varga J; Zink A; Furst DE; ;
    J Rheumatol; 2009 Oct; 36(10):2356-61. PubMed ID: 19820225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
    Spiera R; Khanna D; Kuwana M; Furst DE; Frech TM; Hummers L; Stevens W; Matucci-Cerinic M; Baron M; Distler O; Dgetluck N; Bloom BJ; Dinh Q; White B; Denton CP
    Clin Exp Rheumatol; 2021; 39 Suppl 131(4):124-133. PubMed ID: 34323681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity.
    Zheng B; Nevskaya T; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Feb; 59(2):398-406. PubMed ID: 31359048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
    Domsic RT; Medsger TA; Gao S; Laffoon M; Huang S; Wisniewski S; Spino C; Steen V; Lafyatis R; Khanna D
    Rheumatology (Oxford); 2023 Apr; 62(4):1543-1551. PubMed ID: 36031807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
    Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-assessment of skin tightness severity by scleroderma patients.
    Daungkum K; Foocharoen C; Mahakkanukrauh A; Suwannaroj S; Thinkhamrop B; Nanagara R
    Int J Rheum Dis; 2016 Oct; 19(10):989-995. PubMed ID: 27126197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database.
    Carreira PE; Carmona L; Joven BE; Loza E; Andreu JL; Riemekasten G; Vettori S; Balbir-Gurman A; Airò P; Walker UA; Damjanov N; Matucci-Cerinic M; Ananieva LP; Rednic S; Czirják L; Distler O; Farge D; Hesselstrand R; Corrado A; Caramaschi P; Tikly M; Allanore Y;
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):68-75. PubMed ID: 30277860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences Sustained Between Diffuse and Limited Forms of Juvenile Systemic Sclerosis in an Expanded International Cohort.
    Foeldvari I; Klotsche J; Kasapcopur O; Adrovic A; Terreri MT; Sakamoto AP; Stanevicha V; Sztajnbok F; Anton J; Feldman B; Alexeeva E; Katsicas M; Smith V; Avcin T; Marrani E; Kostik M; Lehman T; Sifuentes-Giraldo WA; Vasquez-Canizares N; Appenzeller S; Janarthanan M; Moll M; Nemcova D; Patwardhan A; Santos MJ; Sawhney S; Schonenberg-Meinema D; Battagliotti C; Berntson L; Bica B; Brunner J; Costa-Reis P; Eleftheriou D; Harel L; Horneff G; Kaiser D; Kallinich T; Lazarevic D; Minden K; Nielsen S; Nuruzzaman F; Uziel Y; Helmus N; Torok KS
    Arthritis Care Res (Hoboken); 2022 Oct; 74(10):1575-1584. PubMed ID: 33787070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais.
    Foocharoen C; Watcharenwong P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
    Int J Rheum Dis; 2017 Oct; 20(10):1572-1581. PubMed ID: 28296274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
    Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
    Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.